News for Homology Medicines Stock (FIXX)

Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting

GlobeNewsWire • 03/15/23

Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research • 03/10/23

Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

GlobeNewsWire • 03/09/23

Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer

GlobeNewsWire • 03/09/23

Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

GlobeNewsWire • 03/02/23

Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting

GlobeNewsWire • 02/22/23

Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs

GlobeNewsWire • 01/04/23

5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050%

PennyStocks • 11/17/22

Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research • 11/10/22

Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights

GlobeNewsWire • 11/10/22

Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting

GlobeNewsWire • 10/27/22

Homology Medicines to Participate at Upcoming Conferences

GlobeNewsWire • 10/06/22

Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer

GlobeNewsWire • 09/06/22

Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research • 08/15/22

Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update

GlobeNewsWire • 08/15/22

Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

GlobeNewsWire • 08/11/22

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

GlobeNewsWire • 07/05/22

Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU

GlobeNewsWire • 06/29/22

FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Limited Shareholders

Newsfile Corp • 05/24/22

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline - FIXX

PRNewsWire • 05/24/22

Homology Class Action: Levi & Korsinsky Reminds Homology Medicines, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 24, 2022 - FIXX

Newsfile Corp • 05/24/22

FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Homology Medicines, Inc. (FIXX) Shareholders of Class Action Last Few Hours to Actively Participate

Newsfile Corp • 05/24/22

FIXX DEADLINE TODAY: ROSEN, A TOP RANKED FIRM, Encourages Homology Medicines, Inc. Investors With Losses to Secure Counsel Before Important May 24 Deadline in Securities Class Action - FIXX

Newsfile Corp • 05/24/22

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Homology Medicines, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 05/24/22

FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Shareholders

PRNewsWire • 05/24/22